[{"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsIntervention group: This group will be treated by Fluvoxamine drug. The drug dosage will be increased up to 300 mg daily depending on the patients tolerance to the drug. At first, 50 mg will be prescribed per night. after 2 days, 100 mg will be prescribed per night. After 4 days, 100 mg will be prescribed per afternoon and 100 mg will be prescribed per night. After 4 days, 100 mg will be prescribed per morning, 100 mg will be prescribed per afternoon and 100 mg will be prescribed per night. Pharmaceutical companies including Abidi and Sobhan produce Fluvoxamine drug in Iran. Thus, the Fluvoxamine produced by each of the mentioned pharmaceutical companies will be used in the current project.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "TODO Treatment - DrugsControl group: This group will not receive Fluvoxamine drug. But all of the members undergo COVID-19 treatment in Intensive Care Unit under the supervision of the specialist physician, like the intervention group.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 522, "treatment_name": "Fluvoxamine", "treatment_type": "Central nervous system agents", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]